Clinical Characteristics of Coronary Drug-Eluting Stent Fracture: Insights from a Two-Center DES Registry
Kyung-Woo PARK; Jin-Joo PARK; In-Ho CHAE; Jae-Bin SEO; Han-Mo YANG; Hae-Young LEE; Hyun-Jae KANG; Young-Seok CHO; Tae-Jin YEON; Woo-Young CHUNG; Bon-Kwon KOO; Dong-Ju CHOI; Byung-Hee OH; Young-Bae PARK; Hyo-Soo KIM.
Journal of Korean Medical Science
; : 53-58, 2011.
Artículo
en Inglés
| WPRIM | ID: wpr-137392
Stent fracture (SF) has been implicated as a risk factor for in-stent restenosis, but its incidence and clinical characteristics are not well established. Therefore we investigated the conditions associated with stent fracture and its clinical presentation and outcome. Between 2004 and 2007, consecutive cases of SF were collected from the Seoul National University Hospital. Clinical characteristics and outcome of patients with fractured stents were compared with a ten-fold cohort of age and gender matched controls (n = 236). A total of 4,845 patients received percutaneous coronary intervention and 3,315 patients (68.4%) underwent angiographic follow-up. Twenty-eight fractured stents were observed in 24 patients. The incidence of SF was 0.89% for sirolimus-eluting stents (SES) and 0.09% for paclitaxel-eluting stents. Chronic kidney disease, stent implantation in the right coronary artery (RCA), and SES use were independent predictors of drug-eluting stent fracture by multivariate analysis. SF was significantly associated with binary restenosis (11.4% vs 41.7%, P < 0.001) and increased risk of target lesion revascularization (8.1% vs 33.3%, P = 0.001). Patients with SF but without significant restenosis showed excellent outcome despite only medical treatment. In conclusion, SF is associated with increased rates of restenosis and repeat revascularization. Significant risk factors include chronic kidney disease, RCA intervention, and SES use.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados